Covid-19

#Clinical trials #Covid-19 #Healthcare #Research

First UK trial to assess use of antivirals to treat Covid-19 set to begin 

The first clinical trial in the UK to investigate whether antiviral drugs could help reduce the severity of Covid-19 is due to start, led by the University of Oxford and delivered in Wales by Cardiff University in partnership with Public Health Wales and Health and Care Research Wales. Cardiff University staff… Read More

#News

#Covid variants #Covid-19 #Public health

PerkinElmer launches kit to strengthen SARS-CoV-2 surveillance 

PerkinElmer has announced the research use only (RUO) launch of the NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to accelerate the detection of SARS-CoV-2 variants, which will allow laboratories to increase sequencing throughput and make reliable variant identifications.  What is NEXTFLEX?   Using positive SARS-CoV-2 samples, the NEXTFLEX… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug development #Drug discovery

This week in drug discovery (6-10 December) 

News round-up by DDW’s Megan Thomas for 6-10 December  In the wake of the discovery of the Omicron Covid-19 variant globally, DDW’s Megan Thomas rounds up five news stories which show the strides being made to understand and fight this variant across the drug discovery industry. … Read More

#News

#Collaboration #Covid-19 #Research

Can this chewing gum reduce SARS-CoV-2 transmission? 

According to a new study, scientists have found chewing gum laced with a plant-grown protein serves as a “trap” for the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission.  The study  The work, led by Henry Daniell at the University of Pennsylvania’s School… Read More

#Covid-19 #News

#Antibodies #Covid-19 #Nanobodies #Therapeutics

Can llama antibodies help develop a Covid-19 therapy?

Amid the growing threat of a new and potentially more dangerous SARS-CoV-2 variant, scientists are ramping up the quest for Covid treatments. A recent study demonstrates the therapeutic potential of an unusual class of immune proteins: miniature antibodies called nanobodies, derived from llamas. Rockefeller University scientists Michael P. Rout and Brian T. Chait and… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #Plant-based

First plant-based Covid-19 vaccine promising says Medicago and GSK

Results from the Phase III placebo-controlled efficacy study of Medicago’s plant-based Covid-19 vaccine candidate in combination with GlaxoSmithKline’s pandemic adjuvant have shown positive results. Vaccine efficacy was demonstrated in an environment dominated by SARS-CoV-2 variants, unlike most published Phase III efficacy trials for currently licensed Covid-19 vaccines that were conducted… Read More

#Editor's Choice #News #Trending News

#Covid-19 #Monoclonal antibodies #Reagents #Research

Sino Biological launches panel of research reagents for Omicron variant

Sino Biological has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus. The new Omicron product line includes recombinant Omicron spike proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognising the Omicron spike protein, and the Omicron pseudovirus assay CRO service. These… Read More

#News

#Covid-19 #FDA

FDA authorises Eli Lilly Covid therapy for under-12s

Paediatric patients from birth to 12 years old can now be treated with an antibody drug for Covid-19. The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab to be administered together in high-risk paediatric patients for the treatment of mild to… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Drug discovery #Immunology / Virology & Vaccines #Omicron

Preclinical data of drug demonstrates protection against Omicron 

Following the approval of GlaxoSmithKline (GSK) and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), the companies have announced an update, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab.  … Read More

#Covid-19 #News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Omicron #Therapeutics

Breakthrough: New drug for Omicron and coronavirus strains 

Infex Therapeutics scientists have announced a breakthrough in laboratory trials of a new drug to treat Covid-19 and new variants of the disease, such as the Omicron variant.   Infex’s COV-X programme inhibits a new protease target that is responsible for viral replication across the broad spectrum of SARS-CoV-1, MERS-CoV and SARS-CoV-2. As such,… Read More

#Covid-19 #News #Trending News

#Biotechnology #Covid-19 #Drug discovery #Immunology / Virology & Vaccines

Covid-19 treatment cuts hospitalisation and death by 79% 

The Medicines and Healthcare products Regulatory Agency (MHRA), in the UK, has approved GSK and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), after it was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate Covid-19 infection who are at an increased risk of developing severe… Read More

#Covid-19 #News #Trending News

#Biopharmaceuticals #Biotechnology #Clinical trials #Covid-19 #Podcast

Clinical trials and the growing importance of technology: Podcast 

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Read More

#News

#Biopharmaceuticals #Biotechnology #Clinical trials #Covid-19 #Podcast #Sitting Down With

Clinical trials and the growing importance of technology

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Read More

#Podcasts

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna announces strategy to address Omicron SARS-CoV-2 variant 

Moderna has announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.   What is Omicron?  The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen… Read More

#Covid-19 #News #Trending News